Salt Lake City-based Co-Diagnostics, Inc. is a leading molecular diagnostics company that has been in the business of developing, manufacturing, and selling reagents used for diagnostic tests for over eight years. With a presence across the United States and internationally, the company has made its mark in the industry by offering a range of polymerase chain reaction (PCR) diagnostic tests for highly prevalent diseases like COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Notably, Co-Diagnostics goes beyond disease detection and offers three multiplexed tests specific to mosquitos, aimed at identifying diseases carried by the insects. The company also provides a range of molecular tools for the detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Additionally, Co-Diagnostics has a suite of products for identifying genetic traits in plant and animal genomes, alongside a portable PCR device that brings the power of PCR to patients in point-of-care and at-home settings. Moreover, Co-Diagnostics reportedly plans to sell diagnostic equipment from other manufacturers as self-contained lab systems, signaling its intent to broaden its offerings in the market. The company has been in operation since 2013 and continues to lead the field of molecular diagnostics, setting new standards with its range of innovative and reliable diagnostic tests.
Co-Diagnostics Inc's ticker is CODX
The company's shares trade on the NASDAQ stock exchange
They are based in Salt Lake City, Utah
There are 11-50 employees working at Co-Diagnostics Inc
It is codiagnostics.com
Co-Diagnostics Inc is in the Healthcare sector
Co-Diagnostics Inc is in the Diagnostic Substances industry
The following five companies are Co-Diagnostics Inc's industry peers: